Kevan Shokat
凯文·肖卡特
PhD
Professor, Department of Cellular and Molecular Pharmacology细胞与分子药理学系教授
👥Biography 个人简介
Kevan Shokat is a pioneering chemical biologist at UCSF who cracked the 'undruggable' KRAS problem by discovering the G12C covalent binding pocket. His work directly enabled sotorasib and adagrasib, the first approved KRAS inhibitors, transforming lung cancer treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
KRAS G12C Covalent Inhibitor Discovery
Identified a cryptic switch-II pocket on KRAS G12C, enabling covalent inhibitor design. This breakthrough directly led to FDA-approved sotorasib and adagrasib for NSCLC.
Covalent Chemical Biology
Pioneered chemical strategies for targeting oncoproteins previously considered undruggable, establishing a new paradigm for covalent warhead-based drug discovery across oncology.
Representative Works 代表性著作
Drugging an undruggable pocket on KRAS
Nature (2013)
Seminal paper identifying the switch-II pocket on KRAS G12C that enabled the first covalent KRAS inhibitors, launching a new therapeutic era.
Allele-specific inhibitors inactivate mutant RAS isoforms
Science (2015)
Demonstrated selective inhibition of KRAS G12C with covalent compounds, validating the therapeutic strategy that reached clinical approval.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 凯文·肖卡特 的研究动态
Follow Kevan Shokat's research updates
留下邮箱，当我们发布与 Kevan Shokat（University of California, San Francisco）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment